Clinical trial
A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma…
NCT00438009 · Viralytics, Industry · Completed
Key facts
| NCT number | NCT00438009 |
|---|---|
| Title | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) |
| Official title | A Phase I, Open Label, Cohort Study of Two Doses of Cavatak (Coxsackievirus Type A21) Given Intratumourally in Stage IV Melanoma Patients. |
| Lead sponsor | Viralytics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | Coxsackievirus A21 |
| Enrollment | 9 |
| Start date | May 16, 2007 |
| Primary completion | Aug 28, 2009 |
| Completion | Aug 28, 2009 |
| First posted | Feb 21, 2007 |
| Last update posted | Jul 1, 2019 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: